On July 24, Dow Chemical fell 5.02% in regular trading, trading at $29.36/share, with turnover of $45.36 million. The decline came despite the company reporting better-than-expected Q2 results on July 23.

Dow Chemical posted adjusted EPS of $1.44, beating the consensus estimate of $1.28 by 12.5%, while revenue of $12.09 billion also topped the $12.03 billion forecast, marking an increase from $10.10 billion a year earlier. The company also noted that its cost-reduction initiatives delivered over $300 million in Q2 benefits, with its Transform to Win program expected to generate an additional $200 million in savings this year.

However, selling pressure intensified after management stated during the earnings call that ongoing Middle East conflicts have created broad market uncertainty, making it extremely difficult to forecast next-quarter performance. While the company noted increasing orders from China, the market focused on the lack of forward guidance. Additionally, management flagged that building and construction end-market fundamentals remain weak overall. UBS raised its price target on Dow to $32 from $29 while maintaining a Neutral rating, with the analyst consensus mean target at $35.88.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)